Antivirals TRIZ Cases

See how psychrophilic protease enzymes embedded in fabric inactivate viruses and bacteria on co

A bictegravir, emtricitabine, and tenofovir alafenamide regimen addresses limited HIV prophylaxis options with timed post-exposure protection.

Compounds targeting SARS-CoV-2 Mpro and PLpro inhibit viral replication and immune suppression, supporting COVID-19 treatment or prevention.

A multi-herb extract targets severe COVID-19 complications by improving blood oxygen, easing pleural effusion, and supporting vital organ stability.

A nucleoside phosphate prodrug improves in vivo phosphorylation, boosting coronavirus inhibition and speeding viral clearance in COVID-19 treatment.

Nitroxoline-based cysteine protease inhibitors block coronavirus entry and replication while limiting host cell toxicity through selective cathepsin B inhibition.

Overlapping peptide libraries and antigen-presenting cells enable safe expansion of HPV-specific T cells from naive donors without live viruses.

A modified herbal composition blocks spike-ACE2 binding and 3CL protease while reducing inflammation, thrombosis, and lung damage.

A ten-herb TCM composition inhibits spike-ACE2 binding, reduces cytokine release, and slows pulmonary embolism and fibrosis progression.

Combining NS5B and NS5A inhibitors in one fixed-dose therapy improves pan-genotypic HCV suppression while limiting resistance and treatment complexity.

A Neurolaena lobata leaf tincture blocks DHODH and viral pyrimidine supply while avoiding the cytotoxicity seen with synthetic inhibitors.

Small-molecule protease inhibitors use targeted structural tuning to balance potency, selectivity, and oral bioavailability for cancer and viral therapy.

Substituted nucleoside compounds inhibit SARS-CoV-2 RNA polymerase to treat or prevent infection while broadening usable drug forms.

An intranasal peptide conjugate blocks viral entry and reduces SARS-CoV-2 or paramyxovirus transmission without prolonged isolation.

A WS-635 composition case showing how broad coronavirus inhibition can improve treatment effectiveness against SARS-CoV-2 and related infections.

Dose-adjusted maribavir regimens help treat CMV in transplant recipients while managing interactions with CYP3A4 inducers and co-medications.

Computationally identified EC-CREs boost endothelial-specific gene expression, enabling lower vector doses and safer gene therapy.

A five-herb composition is formulated to inhibit SARS-CoV-2 replication in Vero cells and support coronavirus treatment research.

Combining an HIV-1 integrase inhibitor with other anti-HIV agents helps treat resistant HIV strains while addressing side effects and cross-resistance.

Botanical extracts with extracellular and intracellular antiviral action are combined to boost HSV-1 inhibition and reduce resistance risk.

A multi-herb composition inhibits spike-ACE2 binding to block wild-type and variant SARS-CoV-2 entry with minimal cytotoxicity.

Pharmaceutical combinations target RNA viral infection while lowering lung viral titers, neutrophil density, and necrotized cell counts.

Standardized nasturtium and horseradish powders improve oral RSV inhibition while reducing side-effect risks of supportive care.

Cationized nucleases paired with dendrimers improve cell entry and RNase inhibitor evasion to disrupt viral RNA replication.

Dose adjustment and drug-level monitoring help maribavir maintain CMV treatment efficacy while limiting interactions with inducers and co-medications.

An NKG2D CAR with 4-1BB and CD3-zeta domains helps engineered T cells target resistant solid tumors more effectively.

A defined monolayer culture platform replaces embryoid body and serum-based steps to scale homogeneous hematopoietic cell production.

Direct primase inhibition helps treat drug-resistant HSV while lowering viral load, limiting side effects, and sustaining plasma exposure.

A mucoadhesive polymer and clay barrier adheres to mucosa, traps pathogens and allergens, and provides prolonged protection.

Gene-edited CD30 CAR cytotoxic cells target infected CD30-expressing reservoirs to limit reactivation and avoid complex personalized manufacturing.

Aptamer binding and reversible release isolate label-free cells in one step, improving purity, yield, and production-scale cost.

A monolayer tablet combines bictegravir and lenacapavir to cut pill burden while preserving dissolution and pharmacokinetic performance.

Pegylated inositol derivatives inhibit calcium oxalate nucleation and renal cell adhesion to help prevent recurrent kidney stones.

Selective HDAC3/HDAC8 targeting reactivates the EBV lytic phase in cancer cells while limiting off-target effects and supporting antiviral killing.

Targeting mutagenic TLS polymerases helps suppress RNA virus proliferation and reduce genomic instability linked to long-COVID symptoms.

Combining AT-527 and ruzasvir targets HCV through NS5B and NS5A inhibition to reduce viral load and limit drug resistance.

Multiple reactive groups anchor peptide loops to a scaffold, creating bicyclic ligands that target SARS-CoV-2 spike S1 and hinder cell entry.

Managing CYP3A4 inducers and immunosuppressants enables tailored maribavir dosing while preserving CMV treatment efficacy and patient safety.

Culturing CD4/CD8 double-positive T cells with IL-7 and a T-cell receptor activator preserves CD8αβ expression while avoiding NK activity.

CYP3A4 inducers can reduce maribavir exposure, so adaptive dosing supports CMV efficacy while blood-level monitoring limits adverse events.

Aptamers pre-bind ACE2 to block the SARS-CoV-2 Spike interaction, preventing viral entry and replication across multiple coronavirus variants.

Click chemistry links E. coli O-antigens to an SCP carrier to improve functional immune responses across variable serotypes.

Mebendazole targets viral tubulin formation and calmodulin-domain protein kinase 1 to inhibit SARS-CoV-2 entry and replication.

EBV miRNAs can suppress adaptive immunity; miRNA-deficient herpesvirus-like particles preserve virion structure for stronger vaccine responses.

Defined media with BMP, bFGF, WNT, ROCK, and GSK3 pathway modulators support homogeneous, scalable differentiation without serum or embryoid bodies.

This case combines Nafamostat and K777 to block TMPRSS2 and Cathepsin L, delivering synergistic inhibition across SARS-CoV-2 variants.

Botanical extract compositions inhibit viral replication and address drug resistance and latent-virus reactivation across viral infections.

This case examines segmented antiviral compounds tuned for broad-spectrum activity against coronavirus and African Swine Fever virus.

This case uses IAP antagonists to expose dormant HIV reservoirs, enabling immune clearance or antiretroviral treatment.

This case examines inhaled 7-17 amino acid peptides for reducing COVID-19 severity without TNF-receptor-binding activity.

This case uses CI-1040 and PD-0184264 to block the Raf/MEK/ERK pathway, limiting hantavirus replication and mutation-driven resistance.

Combining HCMV gB and pentamer antigens with a Th1 adjuvant strengthens neutralizing antibodies and persistent protection.

Gemcabene mitigates cytokine storm severity by modulating the immune response to prevent respiratory failure and secondary complications.